Huda Salman

My clinical and research interest is to develop therapies that enhance the immune system to fight blood cancer. I serve as the IND holder responsible for the clinical development for the CD4CAR , and the CAR T cells are manufactured under this IND and the GMP conditions at Indiana University. This work is done in collaboration with IcellGene therapeutics. It is designed to treat T cell leukemia and lymphoma. We have treated three patients so far and results were very promising. CD4, the target for this CAR is expressed on CMML and we are not only planning to try this CAR in CMML, but we will be studying mechanisms of response and resistance to this treatment as we go, and also improving on the structure of this CAR to be more effective with the goal of curing CMML.